Clinical Trials Logo

Clinical Trial Summary

Decompensated cirrhosis has a high overall mortality rate. There is a large unmet need for safe and alternative therapeutic potions. This clinical trial is to inspect the efficiency and safety of mesenchymal stem cells (MSCs) therapy for decompensated cirrhosis.


Clinical Trial Description

Decompensated cirrhosis has a high overall mortality rate. Liver transplantation is still the most effective treatment for decompensated cirrhosis. However, the shortage of matched liver sources, high costs, and rejection after liver transplantation restrict the development of liver transplantation. Mesenchymal stem cells (MSC) are a kind of pluripotent stem cells belonging to mesoderm, which mainly exist in connective tissue and organ interstitium. At present, MSC can be isolated and prepared from bone marrow, fat, synovium, bone, muscle, lung, liver, pancreas and amniotic fluid and umbilical cord blood . Due to its wide range of sources and self-proliferation and differentiation ability, MSCs have therapeutic potential for many diseases, including acute and chronic liver diseases. In recent years, our team has carried out a series of clinical trials using umbilical cord-derived MSCs to treat patients with end-stage liver disease, decompensated cirrhosis, primary biliary cholangitis, and status after liver transplantation and found that MSCs therapy can significantly improve patient liver function, reduce post-transplantation rejection, reduce complications, improve quality of life, and improve survival. Other investigators have also found in clinical trials with MSCs from different sources that treatment with MSCs can improve MELD scores or liver function levels to varying degrees. However, some studies have found no significant difference between the treatment group and the control group, and MSCs may differentiate into hepatic stellate cells and have the risk of promoting liver fibrosis, it is believed that MSCs do not favor the improvement of liver function in these studies. Therefore, the therapeutic effects of MSCs need to be further validated by larger multicenter randomized controlled clinical trials. The investigators will do a prospective, double-blind, multicentre, randomised trial to assess treatment with three intravenous doses of MSCs compared with placebo. 240 decompensated cirrhosis patients will be recruited in China.120 patients will receive i.v. transfusion 3 times of MSCs (6.0×10E7 cells per time) and the standard of care as the treated group. In addition, the 120 patients will receive placebo and standard of care as control group. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05121870
Study type Interventional
Source Beijing 302 Hospital
Contact Lei Shi, MD,PhD
Phone 86-10-66949623
Email [email protected]
Status Recruiting
Phase Phase 2
Start date September 1, 2021
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT01701687 - Biomarkers for the Prognosis of Decompensated Alcoholic Liver Disease N/A
Not yet recruiting NCT05086536 - Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis
Recruiting NCT03820271 - New Prognostic Predictive Models of Mortality of Decompensated Cirrhotic Patients Waiting for Liver Transplantation N/A
Completed NCT02219477 - A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis Phase 3
Recruiting NCT04775329 - Primary Prophylaxis for Spontaneous Bacterial Peritonitis Phase 2/Phase 3
Recruiting NCT04422223 - Prospective Cohort Study of Disease and Outcomes in Cirrhosis
Recruiting NCT02786017 - Injectable Collagen Scaffold™ Combined With HUC-MSCs Transplantation for Patients With Decompensated Cirrhosis Phase 1/Phase 2
Completed NCT01326949 - Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Prevention of Variceal Rebleeding in Cirrhotic Patients With Portal Vein Thrombosis N/A
Active, not recruiting NCT03205345 - Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis Phase 2
Recruiting NCT04112199 - A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory Ascites Phase 2
Active, not recruiting NCT05045924 - CirrhoCare in COVID-19: A Pilot, Remote, Home Monitoring Study in Advanced Cirrhosis
Completed NCT03547895 - Management of Decompensated HCV Cirrhotic Patients N/A
Completed NCT01902511 - A Trial to Study the Influence of Growth Factors on Bone Marrow and Hepatic Regeneration in Patients With Decompensated Cirrhosis. N/A
Completed NCT01410591 - TIPS With 8- OR 10-mm Covered Stent for Preventing Variceal Rebleeding N/A
Completed NCT01370161 - Early TIPS With Polytetrafluoroethylene (PTFE) Covered Stents for Acute Variceal Bleeding in Patients With Advanced Cirrhosis N/A
Active, not recruiting NCT03214796 - Effect of Albumin Infusion on Oxidative Albumin Modification, Albumin Binding Capacity and Plasma Thiol Status
Enrolling by invitation NCT00663182 - Entecavir for Patients With Decompensated Hepatitis B Virus (HBV)-Related Cirrhosis Phase 4
Recruiting NCT04208776 - Efficacy of Combination of Midodrine With Propranolol in Preventing First Bleed in Decompensated Cirrhotics With Severe Ascites. N/A
Completed NCT02467322 - To Study The Incidence And Outcome Of Paracentesis Induced Circulatory Dysfunction in Decompensated Cirrhotics Undergoing Less Than 5 Litres Of Ascitic Fluid Tap With Or Without Albumin Infusion. N/A
Terminated NCT01701297 - VSL#3 and Spontaneous Bacterial Peritonitis Phase 2